SRP 1001
Alternative Names: ARO-DUX4; SRP-1001Latest Information Update: 16 Feb 2025
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action DUX4L1 protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Facioscapulohumeral muscular dystrophy
Most Recent Events
- 10 Feb 2025 Arrowhead Pharmaceuticals completes global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical programme
- 27 Nov 2024 Arrowhead Pharmaceuticals enters into global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical siRNA programme
- 04 Sep 2023 Phase-I/II clinical trials in Facioscapulohumeral muscular dystrophy in New Zealand (IV) prior to September 2023 (Arrowhead Pharmaceuticals pipeline, September 2023) (NCT06131983)